ArticleJournal of clinical microbiology2012
First report of an extensively drug-resistant VIM-2 metallo-β-lactamase-producing Brevundimonas diminuta clinical isolate.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Polymicrobial Catheter-Related Bloodstream Infection InvolvingMicroorganisms · 2026Article
- Coinfection meningitis caused by Lysinibacillus sphaericus and Brevundimonas diminuta in a pediatric patient with cerebral atrophy: a case report.Journal of medical case reports · 2026Article
- Article
- Resveratrol Alleviated Intensive Exercise-Induced Fatigue Involving in Inhibiting Gut Inflammation and Regulating Gut Microbiota.Food science & nutrition · 2025Article
- Brevundimonas diminuta Bacteremia in a Case of Adrenal Insufficiency: A Case Report and Literature Review.Cureus · 2024Article
- Yearlong analysis of bacterial diversity in hospital sink drains: culturomics, antibiotic resistance and implications for infection control.Frontiers in microbiology · 2024Article
- Article
- Brevundimonas diminuta-Induced Lung Abscess in an Immunocompetent Adult: A Rare Case Report.Cureus · 2023Article
- Article
- Article
- First Isolation and Clinical Case ofMedicina (Kaunas, Lithuania) · 2021Article
- Carbapenem Resistance among Marine Bacteria-An Emerging Threat to the Global Health Sector.Microorganisms · 2021Review
- Coming from the Wild: Multidrug Resistant Opportunistic Pathogens Presenting a Primary, Not Human-Linked, Environmental Habitat.International journal of molecular sciences · 2021Review
- Article
- Diversity and Genetic Basis for Carbapenem Resistance in a Coastal Marine Environment.Applied and environmental microbiology · 2020Article
- Brevundimonas spp: Emerging global opportunistic pathogens.Virulence · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the literature, only three Brevundimonas diminuta environmental isolates carrying metallo-β-lactamase genes were recently published. However, so far, no B. diminuta clinical isolates carrying these carbapenem resistance genes have been described. Here we report the first VIM-2 metallo-β-lactamase-producing B. diminuta clinical isolate obtained from an immunocompromised patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.